Sana Biotechnology Announces Appointments to its Board of Directors
Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors
News provided by
Share this article
Share this article
SEATTLE, Jan. 8, 2021 /PRNewswire/ Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors. Josh, Alise, and Michelle all share a passion and commitment to our long-term vision of engineering cells to make medicines that improve the lives of patients, said Sana President and CEO Steve Harr. The diversity of their experiences, backgrounds, and expertise will be critical to our strategy, decision-making, risk-management, and governance. I look forward to working with them to continue to build Sana.